BACKGROUND. Medical practice patterns change in response to a variety of stimuli, one of which may be the publication of the results of randomized clinical trials. We assessed the temporal association between the publication of clinical trials on myocardial infarction and changes in treatment practices for this disorder. METHODS. We analyzed the use of aspirin before and after myocardial infarction and that of calcium antagonists after myocardial infarction in 2231 survivors of myocardial infarction enrolled in the Survival and Ventricular Enlargement (SAVE) study over a three-year period (from January 1987 through January 1990). The proportion of patients using these treatments was analyzed before and after the publication dates of three clinical trials: the Physicians' Health Study, published in January 1988, which supported the use of aspirin to prevent a first myocardial infarction; the Second International Study of Infarct Survival (ISIS-2), published in August 1988, which supported the use of aspirin after myocardial infarction; and the Multicenter Diltiazem Postinfarction Trial, published in August 1988, which reported a deleterious effect of diltiazem in some patients after myocardial infarction. RESULTS. The use of aspirin before myocardial infarction increased from 16.2 percent to 23.9 percent between January 1987 and January 1990 (P less than 0.001). Enrollment in the study after the publication of the Physicians' Health Study independently predicted aspirin use before myocardial infarction (odds ratio, 1.43; 95 percent confidence interval, 1.11 to 1.85). The use of aspirin after myocardial infarction increased from 38.8 percent to 71.9 percent (P less than 0.001) during the three-year study period. Enrollment in the study after the publication of ISIS-2 independently predicted the use of aspirin after myocardial infarction (odds ratio, 2.28; 95 percent confidence interval, 1.89 to 2.76). The use of calcium antagonists after myocardial infarction decreased from 57.1 percent to 33.1 percent (P less than 0.001) during the study period. Enrollment in the study after the publication of the Multicenter Diltiazem Postinfarction Trial independently predicted the use of calcium antagonists after myocardial infarction (odds ratio, 0.47; 95 percent confidence interval, 0.39 to 0.57). CONCLUSIONS. These observations suggest that randomized clinical trials have a measurable influence on medical practice patterns.
Source Information
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
This article has been cited by other articles:
Bartholomew, L. K., Cushman, W. C, Cutler, J. A, Davis, B. R, Dawson, G., Einhorn, P. T, Graumlich, J. F, Piller, L. B, Pressel, S., Roccella, E. J, Simpson, L., Whelton, P. K, Williard, A., ALLHAT Collaborative Research Group,
(2009). Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials
6: 329-343
[Abstract]
Lee, T. H.
(2007). Eulogy for a Quality Measure. NEJM
357: 1175-1177
[Full Text]
Hauptman, P. J., Schnitzler, M. A., Swindle, J., Burroughs, T. E.
(2006). Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.. JAMA
296: 1877-1884
[Abstract][Full Text]
Hennekens, C. H., Sechenova, O., Hollar, D., Serebruany, V. L.
(2006). Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions.. J CARDIOVASC PHARMACOL THER
11: 170-176
[Abstract]
Austin, P. C, Mamdani, M. M, Juurlink, D. N
(2006). How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins. The Annals of Pharmacotherapy
40: 1047-1051
[Abstract][Full Text]
Gulizia, M., Mangiameli, S., Chiaranda, G., Spadola, V., Di Giovanni, N., Colletti, A., Bulla, V., Circo, A., Pensabene, O., Vasquez, L., Vaccaro, I., Grammatico, A., on behalf of PITAGORA Study Investigators,
(2006). Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.. Europace
8: 302-305
[Abstract][Full Text]
Majumdar, S. R., McAlister, F. A., Furberg, C. D.
(2004). From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol
43: 1738-1742
[Abstract][Full Text]
Stafford, R. S., Furberg, C. D., Finkelstein, S. N., Cockburn, I. M., Alehegn, T., Ma, J.
(2004). Impact of Clinical Trial Results on National Trends in {alpha}-Blocker Prescribing, 1996-2002. JAMA
291: 54-62
[Abstract][Full Text]
Velazquez, E. J., Pfeffer, M. A., McMurray, J. V., Maggioni, A. P., Rouleau, J.-L., Van de Werf, F., Kober, L., White, H. D., Swedberg, K., Leimberger, J. D., Gallo, P., Sellers, M. A., Edwards, S., Henis, M., Califf, R. M., for the VALIANT Investigators,
(2003). VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail
5: 537-544
[Abstract][Full Text]
Austin, P. C., Mamdani, M. M., Tu, K., Jaakkimainen, L.
(2003). Prescriptions for Estrogen Replacement Therapy in Ontario Before and After Publication of the Women's Health Initiative Study. JAMA
289: 3241-3242
[Full Text]
Tu, K., Mamdani, M. M., Jacka, R. M., Forde, N. J., Rothwell, D. M., Tu, J. V.
(2003). The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ
168: 553-557
[Abstract][Full Text]
Oishi, Y., Ozono, R., Yano, Y., Teranishi, Y., Akishita, M., Horiuchi, M., Oshima, T., Kambe, M.
(2003). Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling. Hypertension
41: 814-818
[Abstract][Full Text]
Henrion, D., Kubis, N., Levy, B. I.
(2001). Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation. Hypertension
38: 1150-1157
[Abstract][Full Text]
Baessler, A, Hengstenberg, C, Holmer, S, Fischer, M, Mayer, B, Hubauer, U, Klein, G, Riegger, G, Schunkert, H
(2001). Long-term effects of in-hospital cardiac rehabilitation on the cardiac risk profile. A case-control study in pairs of siblings with myocardial infarction. Eur Heart J
22: 1111-1118
[Abstract]
Brophy, J. M., Joseph, L., Rouleau, J. L.
(2001). {beta}-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. ANN INTERN MED
134: 550-560
[Abstract][Full Text]
Jackevicius, C. A., Anderson, G. M., Leiter, L., Tu, J. V.
(2001). Use of the Statins in Patients After Acute Myocardial Infarction: Does Evidence Change Practice?. Arch Intern Med
161: 183-188
[Abstract][Full Text]
Gross, C. P., Steiner, C. A., Bass, E. B., Powe, N. R.
(2000). Relation Between Prepublication Release of Clinical Trial Results and the Practice of Carotid Endarterectomy. JAMA
284: 2886-2893
[Abstract][Full Text]
Pilote, L., Lavoie, F., Ho, V., Eisenberg, M. J.
(2000). Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ
163: 31-36
[Abstract][Full Text]
Stafford, R. S.
(2000). Aspirin Use Is Low Among United States Outpatients With Coronary Artery Disease. Circulation
101: 1097-1101
[Abstract][Full Text]
St. John Sutton, M.
(2000). Aortic stiffness: a predictor of acute coronary events?. Eur Heart J
21: 342-344
Bart, B.A., Ertl, G., Held, P., Kuch, J., Maggioni, A.P., McMurray, J., Michelson, E.L., Rouleau, J.L., Warner Stevenson, L., Swedberg, K., Young, J.B., Yusuf, S., Sellers, M.A., Granger, C.B., Califf, R.M., Pfeffer, M.A., for the SPICE investigators,
(1999). Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J
20: 1182-1190
[Abstract]
The Study Group on Diagnosis of the Working Group,
(1999). Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Fail
1: 139-144
[Abstract][Full Text]
McCormick, D., Gurwitz, J. H., Lessard, D., Yarzebski, J., Gore, J. M., Goldberg, R. J.
(1999). Use of Aspirin, {beta}-Blockers, and Lipid-Lowering Medications Before Recurrent Acute Myocardial Infarction: Missed Opportunities for Prevention?. Arch Intern Med
159: 561-567
[Abstract][Full Text]
Spargias, K S, Hall, A S, Greenwood, D C, Ball, S G
(1999). beta Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart
81: 25-32
[Abstract][Full Text]
Giugliano, R. P., Camargo, C. A. Jr, Lloyd-Jones, D. M., Zagrodsky, J. D., Alexis, J. D., Eagle, K. A., Fuster, V., O'Donnell, C. J.
(1998). Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina: Potential Impact of Practice Guidelines. Arch Intern Med
158: 1113-1120
[Abstract][Full Text]
Brass, L. M., Krumholz, H. M., Scinto, J. M., Radford, M.
(1997). Warfarin Use Among Patients With Atrial Fibrillation. Stroke
28: 2382-2389
[Abstract][Full Text]
Collins, R., Peto, R., Baigent, C., Sleight, P.
(1997). Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. NEJM
336: 847-860
[Full Text]
Soumerai, S. B., McLaughlin, T. J., Spiegelman, D., Hertzmark, E., Thibault, G., Goldman, L.
(1997). Adverse Outcomes of Underuse of {beta}-Blockers in Elderly Survivors of Acute Myocardial Infarction. JAMA
277: 115-121
[Abstract]
Goldstein, S.
(1996). {beta}-Blockers in Hypertensive and Coronary Heart Disease. Arch Intern Med
156: 1267-1276
[Abstract]
Col, N. F., McLaughlin, T. J., Soumerai, S. B., Hosmer, D. W. Jr, Yarzebski, J., Gurwitz, J. H., Gore, J. M., Goldberg, R. J.
(1996). The Impact of Clinical Trials on the Use of Medications for Acute Myocardial Infarction: Results of a Community-Based Study. Arch Intern Med
156: 54-60
[Abstract]
Krumholz, H. M., Radford, M. J., Ellerbeck, E. F., Hennen, J., Meehan, T. P., Petrillo, M., Wang, Y., Kresowik, T. F., Jencks, S. F.
(1995). Aspirin in the Treatment of Acute Myocardial Infarction in Elderly Medicare Beneficiaries : Patterns of Use and Outcomes. Circulation
92: 2841-2847
[Abstract][Full Text]
Pilote, L., Califf, R. M., Sapp, S., Miller, D. P., Mark, D. B., Weaver, W. D., Gore, J. M., Armstrong, P. W., Ohman, E. M., Topol, E. J., The GUSTO-1 Investigators,
(1995). Regional Variation across the United States in the Management of Acute Myocardial Infarction. NEJM
333: 565-572
[Abstract][Full Text]
Avanzini, F., Latini, R., Maggioni, A., Colombo, F., Santoro, E., Franzosi, M. G., Tognoni, G., GISSI Investigators,
(1995). Antiarrhythmic Drug Prescription in Patients After Myocardial Infarction in the Last Decade: Experience of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI). Arch Intern Med
155: 1041-1045
[Abstract]
Pauly, M. V.
(1995). Practice Guidelines: Can They Save Money? Should They?. J Law Med Ethics
23: 65-74
Pfeffer, M. A.
(1995). ACE Inhibition in Acute Myocardial Infarction. NEJM
332: 118-120
[Full Text]
Ayanian, J. Z., Hauptman, P. J., Guadagnoli, E., Antman, E. M, Pashos, C. L., McNeil, B. J.
(1994). Knowledge and Practices of Generalist and Specialist Physicians Regarding Drug Therapy for Acute Myocardial Infarction. NEJM
331: 1136-1142
[Abstract][Full Text]
Gurwitz, J. H., Goldberg, R. J., Chen, Z., Gore, J. M., Alpert, J. S.
(1994). Recent Trends in Hospital Mortality of Acute Myocardial Infarction--the Worcester Heart Attack Study: Have Improvements Been Realized for All Age Groups?. Arch Intern Med
154: 2202-2208
[Abstract]
Tanenbaum, S. J.
(1994). Knowing and Acting in Medical Practice: The Epistemological Politics of Outcomes Research. Journal of Health Politics, Policy and Law
19: 27-44
[Abstract]
Hennekens, C. H., Jonas, M. A., Buring, J. E.
(1994). The Benefits of Aspirin in Acute Myocardial Infarction: Still a Well-Kept Secret in the United States. Arch Intern Med
154: 37-40
[Abstract]
Laffel, G. L., Berwick, D. M.
(1993). Quality Health Care. JAMA
270: 254-255
[Abstract]
Previous
